GHB use among Australians: characteristics, use patterns and associated harm.

Area of Science:

• Drug Use and Addiction Research
• Neuroscience and Pharmacology
• Public Health and Harm Reduction

Background:

• Gamma-hydroxybutyrate (GHB) is a central nervous system depressant with a history of recreational use.
• Understanding the user demographics and associated risks of GHB is crucial for public health interventions.
• Previous research has indicated potential harms, but detailed user characteristics and side effect profiles require further investigation.

Purpose of the Study:

• To characterize gamma-hydroxybutyrate (GHB) users.
• To investigate GHB and polydrug use patterns among users.
• To determine the spectrum and prevalence of harms associated with GHB use.

Main Methods:

• A structured interview was administered to 76 individuals reporting GHB use.
• Data collected included user demographics, GHB usage patterns, concurrent drug use, and experienced adverse effects.
• Statistical analysis was performed to identify correlations between GHB use, polydrug use, and reported harms.

Main Results:

• GHB users were characterized as a stable, highly educated, and well-functioning group.
• GHB was frequently used in conjunction with other drugs, indicating polydrug use patterns.
• A high proportion (99%) of users reported at least one negative side effect, with a mean of 6.5 side effects.
• Specific adverse events included unconsciousness (52%), vomiting (53%), profuse sweating (58%), and seizures (8%).

Conclusions:

• Despite often limited experience with GHB, users report a high incidence of significant adverse effects.
• Polydrug use in conjunction with GHB appears to be common and may exacerbate associated risks.
• GHB use, particularly in a polydrug context, is associated with substantial health risks requiring attention.